The international medical charity Doctors Without Borders has called on leading pharmaceutical corporations and "all insulin ...

A study in the Journal of the American Chemical Society reports steps toward making inhalable mRNA medicines a possibility.

Lixisenatide is a daily injection. It is no longer available in the U.S. [14] Adlyxin: Name-brand version of Lixisenatide ...

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

SQL injection vulnerabilities occur when an attacker can interfere with the queries that an application makes to its database. You can use Burp to test for these vulnerabilities: Professional Use Burp ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Elementary teachers and veteran K-12 educators were the least likely to recommend people pursue teaching as a career, according to a Pew Research Center survey of public school teachers.

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.